Evvy secures US$40m for AI-powered vaginal microbiome testing

Evvy has raised US$40m to expand its vaginal microbiome platform into reproductive healthcare, starting with fertility and IVF.

The series B funding will also support the expansion of EvvyAI, the data and artificial intelligence platform behind the company’s vaginal healthcare business.

The round brings Evvy’s total capital raised to nearly US$60m across three funding rounds since its launch.

Priyanka Jain, Evvy chief executive and co-founder, said: “Thirty per cent of infertility is categorised as unexplained.

“When you think about the immense emotional and financial effort required to produce a healthy embryo, transferring that embryo into an unexamined, inflamed environment is heartbreaking.

“By measuring and modulating the microbiome proactively, we can tangibly improve clinical outcomes.”

Evvy says it has served more than 100,000 patients and partnered with 3,000 healthcare practitioners.

The company also says 96 per cent of patients opt to contribute their data anonymously to clinical research, contributing to its dataset on the vaginal microbiome and women’s health outcomes.

Its vaginal microbiome testing uses metagenomic sequencing.

Evvy’s at-home Vaginal Health Test analyses more than 700 bacteria and fungi from a vaginal swab and provides clinician-reviewed results, personalised insights and access to prescription treatment where appropriate.

The company’s fertility work builds on 13 peer-reviewed publications and studies conducted in 2025 involving more than 1,000 real-world patients.

The funding round was led by Catalio Capital and included U.S. Fertility through its U.S. Fertility Innovation Fund and Labcorp Venture Fund.

Existing investors General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg and Foreground Capital also participated.

Jacob Vogelstein, co-founder and managing partner at Catalio Capital, said: “Its combination of proprietary data, clinical evidence and a growing biomarker discovery engine creates an entirely new foundation for precision women’s healthcare.

“We believe Evvy is building the data platform that will define this category for decades to come.”

Evvy has also expanded into UTI testing, probiotics, suppositories and other vaginal health treatments.